Global Long-acting Injectable Antipsychotics (LAIs) Market Growth 2024-2030
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Long-acting Injectable Antipsychotics (LAIs) by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Long-acting Injectable Antipsychotics (LAIs) by Country/Region, 2019, 2023 & 2030 2.2 Long-acting Injectable Antipsychotics (LAIs) Segment by Type 2.2.1 First-generation 2.2.2 Second-generation 2.3 Long-acting Injectable Antipsychotics (LAIs) Sales by Type 2.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) 2.3.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue and Market Share by Type (2019-2024) 2.3.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Type (2019-2024) 2.4 Long-acting Injectable Antipsychotics (LAIs) Segment by Application 2.4.1 Schizophrenia 2.4.2 Bipolar Disorder 2.4.3 Other 2.5 Long-acting Injectable Antipsychotics (LAIs) Sales by Application 2.5.1 Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2019-2024) 2.5.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue and Market Share by Application (2019-2024) 2.5.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Long-acting Injectable Antipsychotics (LAIs) Breakdown Data by Company 3.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Company (2019-2024) 3.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company (2019-2024) 3.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Company (2019-2024) 3.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Company (2019-2024) 3.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company (2019-2024) 3.3 Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Company 3.4 Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Product Location Distribution 3.4.2 Players Long-acting Injectable Antipsychotics (LAIs) Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Long-acting Injectable Antipsychotics (LAIs) by Geographic Region 4.1 World Historic Long-acting Injectable Antipsychotics (LAIs) Market Size by Geographic Region (2019-2024) 4.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Long-acting Injectable Antipsychotics (LAIs) Market Size by Country/Region (2019-2024) 4.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Annual Sales by Country/Region (2019-2024) 4.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue by Country/Region (2019-2024) 4.3 Americas Long-acting Injectable Antipsychotics (LAIs) Sales Growth 4.4 APAC Long-acting Injectable Antipsychotics (LAIs) Sales Growth 4.5 Europe Long-acting Injectable Antipsychotics (LAIs) Sales Growth 4.6 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Growth 5 Americas 5.1 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country 5.1.1 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) 5.1.2 Americas Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) 5.2 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) 5.3 Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region 6.1.1 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024) 6.1.2 APAC Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2024) 6.2 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) 6.3 APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Long-acting Injectable Antipsychotics (LAIs) by Country 7.1.1 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) 7.1.2 Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) 7.2 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) 7.3 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) by Country 8.1.1 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) 8.1.2 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) 8.2 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) 8.3 Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Long-acting Injectable Antipsychotics (LAIs) 10.3 Manufacturing Process Analysis of Long-acting Injectable Antipsychotics (LAIs) 10.4 Industry Chain Structure of Long-acting Injectable Antipsychotics (LAIs) 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Long-acting Injectable Antipsychotics (LAIs) Distributors 11.3 Long-acting Injectable Antipsychotics (LAIs) Customer 12 World Forecast Review for Long-acting Injectable Antipsychotics (LAIs) by Geographic Region 12.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size Forecast by Region 12.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Region (2025-2030) 12.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Type (2025-2030) 12.7 Global Long-acting Injectable Antipsychotics (LAIs) Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Otsuka Pharmaceutical 13.1.1 Otsuka Pharmaceutical Company Information 13.1.2 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.1.3 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Otsuka Pharmaceutical Main Business Overview 13.1.5 Otsuka Pharmaceutical Latest Developments 13.2 CHEPLAPHARM Arzneimittel GmbH 13.2.1 CHEPLAPHARM Arzneimittel GmbH Company Information 13.2.2 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.2.3 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 CHEPLAPHARM Arzneimittel GmbH Main Business Overview 13.2.5 CHEPLAPHARM Arzneimittel GmbH Latest Developments 13.3 Alkermes Pharma Ireland Limited 13.3.1 Alkermes Pharma Ireland Limited Company Information 13.3.2 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.3.3 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Alkermes Pharma Ireland Limited Main Business Overview 13.3.5 Alkermes Pharma Ireland Limited Latest Developments 13.4 Essential Pharma 13.4.1 Essential Pharma Company Information 13.4.2 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.4.3 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Essential Pharma Main Business Overview 13.4.5 Essential Pharma Latest Developments 13.5 Janssen Pharmaceuticals 13.5.1 Janssen Pharmaceuticals Company Information 13.5.2 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.5.3 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Janssen Pharmaceuticals Main Business Overview 13.5.5 Janssen Pharmaceuticals Latest Developments 13.6 Indivior UK Limited 13.6.1 Indivior UK Limited Company Information 13.6.2 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.6.3 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Indivior UK Limited Main Business Overview 13.6.5 Indivior UK Limited Latest Developments 13.7 Qilu Pharmaceutical 13.7.1 Qilu Pharmaceutical Company Information 13.7.2 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.7.3 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Qilu Pharmaceutical Main Business Overview 13.7.5 Qilu Pharmaceutical Latest Developments 13.8 Lvye Pharmaceutical 13.8.1 Lvye Pharmaceutical Company Information 13.8.2 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications 13.8.3 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Lvye Pharmaceutical Main Business Overview 13.8.5 Lvye Pharmaceutical Latest Developments 14 Research Findings and Conclusion
List of Tables Table 1. Long-acting Injectable Antipsychotics (LAIs) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions) Table 2. Long-acting Injectable Antipsychotics (LAIs) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions) Table 3. Major Players of First-generation Table 4. Major Players of Second-generation Table 5. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units) Table 6. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) Table 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2019-2024) & ($ million) Table 8. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2024) Table 9. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Type (2019-2024) & (US$/Unit) Table 10. Global Long-acting Injectable Antipsychotics (LAIs) Sale by Application (2019-2024) & (K Units) Table 11. Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2019-2024) Table 12. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2019-2024) & ($ million) Table 13. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2019-2024) Table 14. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Application (2019-2024) & (US$/Unit) Table 15. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Company (2019-2024) & (K Units) Table 16. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company (2019-2024) Table 17. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Company (2019-2024) & ($ millions) Table 18. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company (2019-2024) Table 19. Global Long-acting Injectable Antipsychotics (LAIs) Sale Price by Company (2019-2024) & (US$/Unit) Table 20. Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Producing Area Distribution and Sales Area Table 21. Players Long-acting Injectable Antipsychotics (LAIs) Products Offered Table 22. Long-acting Injectable Antipsychotics (LAIs) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) Table 23. New Products and Potential Entrants Table 24. Market M&A Activity & Strategy Table 25. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Region (2019-2024) & (K Units) Table 26. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Geographic Region (2019-2024) Table 27. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Geographic Region (2019-2024) & ($ millions) Table 28. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Geographic Region (2019-2024) Table 29. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Country/Region (2019-2024) & (K Units) Table 30. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2019-2024) Table 31. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Country/Region (2019-2024) & ($ millions) Table 32. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country/Region (2019-2024) Table 33. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units) Table 34. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2024) Table 35. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & ($ millions) Table 36. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units) Table 37. Americas Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) & (K Units) Table 38. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024) & (K Units) Table 39. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2019-2024) Table 40. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2024) & ($ millions) Table 41. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units) Table 42. APAC Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) & (K Units) Table 43. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units) Table 44. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & ($ millions) Table 45. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units) Table 46. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) & (K Units) Table 47. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units) Table 48. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024) Table 49. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024) & (K Units) Table 50. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024) & (K Units) Table 51. Key Market Drivers & Growth Opportunities of Long-acting Injectable Antipsychotics (LAIs) Table 52. Key Market Challenges & Risks of Long-acting Injectable Antipsychotics (LAIs) Table 53. Key Industry Trends of Long-acting Injectable Antipsychotics (LAIs) Table 54. Long-acting Injectable Antipsychotics (LAIs) Raw Material Table 55. Key Suppliers of Raw Materials Table 56. Long-acting Injectable Antipsychotics (LAIs) Distributors List Table 57. Long-acting Injectable Antipsychotics (LAIs) Customer List Table 58. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Region (2025-2030) & (K Units) Table 59. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Region (2025-2030) & ($ millions) Table 60. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Country (2025-2030) & (K Units) Table 61. Americas Long-acting Injectable Antipsychotics (LAIs) Annual Revenue Forecast by Country (2025-2030) & ($ millions) Table 62. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Region (2025-2030) & (K Units) Table 63. APAC Long-acting Injectable Antipsychotics (LAIs) Annual Revenue Forecast by Region (2025-2030) & ($ millions) Table 64. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Country (2025-2030) & (K Units) Table 65. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Country (2025-2030) & ($ millions) Table 66. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Country (2025-2030) & (K Units) Table 67. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Country (2025-2030) & ($ millions) Table 68. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Type (2025-2030) & (K Units) Table 69. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Type (2025-2030) & ($ millions) Table 70. Global Long-acting Injectable Antipsychotics (LAIs) Sales Forecast by Application (2025-2030) & (K Units) Table 71. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Forecast by Application (2025-2030) & ($ millions) Table 72. Otsuka Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 73. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 74. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 75. Otsuka Pharmaceutical Main Business Table 76. Otsuka Pharmaceutical Latest Developments Table 77. CHEPLAPHARM Arzneimittel GmbH Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 78. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 79. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 80. CHEPLAPHARM Arzneimittel GmbH Main Business Table 81. CHEPLAPHARM Arzneimittel GmbH Latest Developments Table 82. Alkermes Pharma Ireland Limited Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 83. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 84. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 85. Alkermes Pharma Ireland Limited Main Business Table 86. Alkermes Pharma Ireland Limited Latest Developments Table 87. Essential Pharma Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 88. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 89. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 90. Essential Pharma Main Business Table 91. Essential Pharma Latest Developments Table 92. Janssen Pharmaceuticals Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 93. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 94. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 95. Janssen Pharmaceuticals Main Business Table 96. Janssen Pharmaceuticals Latest Developments Table 97. Indivior UK Limited Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 98. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 99. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 100. Indivior UK Limited Main Business Table 101. Indivior UK Limited Latest Developments Table 102. Qilu Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 103. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 104. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 105. Qilu Pharmaceutical Main Business Table 106. Qilu Pharmaceutical Latest Developments Table 107. Lvye Pharmaceutical Basic Information, Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base, Sales Area and Its Competitors Table 108. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolios and Specifications Table 109. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 110. Lvye Pharmaceutical Main Business Table 111. Lvye Pharmaceutical Latest Developments List of Figures Figure 1. Picture of Long-acting Injectable Antipsychotics (LAIs) Figure 2. Long-acting Injectable Antipsychotics (LAIs) Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Long-acting Injectable Antipsychotics (LAIs) Sales Growth Rate 2019-2030 (K Units) Figure 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate 2019-2030 ($ millions) Figure 8. Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 9. Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2023) Figure 10. Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 11. Product Picture of First-generation Figure 12. Product Picture of Second-generation Figure 13. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type in 2023 Figure 14. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2024) Figure 15. Long-acting Injectable Antipsychotics (LAIs) Consumed in Schizophrenia Figure 16. Global Long-acting Injectable Antipsychotics (LAIs) Market: Schizophrenia (2019-2024) & (K Units) Figure 17. Long-acting Injectable Antipsychotics (LAIs) Consumed in Bipolar Disorder Figure 18. Global Long-acting Injectable Antipsychotics (LAIs) Market: Bipolar Disorder (2019-2024) & (K Units) Figure 19. Long-acting Injectable Antipsychotics (LAIs) Consumed in Other Figure 20. Global Long-acting Injectable Antipsychotics (LAIs) Market: Other (2019-2024) & (K Units) Figure 21. Global Long-acting Injectable Antipsychotics (LAIs) Sale Market Share by Application (2023) Figure 22. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application in 2023 Figure 23. Long-acting Injectable Antipsychotics (LAIs) Sales by Company in 2023 (K Units) Figure 24. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Company in 2023 Figure 25. Long-acting Injectable Antipsychotics (LAIs) Revenue by Company in 2023 ($ millions) Figure 26. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Company in 2023 Figure 27. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Geographic Region (2019-2024) Figure 28. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Geographic Region in 2023 Figure 29. Americas Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units) Figure 30. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 ($ millions) Figure 31. APAC Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units) Figure 32. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 ($ millions) Figure 33. Europe Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units) Figure 34. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 ($ millions) Figure 35. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2024 (K Units) Figure 36. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2024 ($ millions) Figure 37. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country in 2023 Figure 38. Americas Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024) Figure 39. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) Figure 40. Americas Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024) Figure 41. United States Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 42. Canada Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 43. Mexico Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 44. Brazil Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 45. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region in 2023 Figure 46. APAC Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2019-2024) Figure 47. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) Figure 48. APAC Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024) Figure 49. China Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 50. Japan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 51. South Korea Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 52. Southeast Asia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 53. India Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 54. Australia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 55. China Taiwan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 56. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country in 2023 Figure 57. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024) Figure 58. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) Figure 59. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024) Figure 60. Germany Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 61. France Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 62. UK Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 63. Italy Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 64. Russia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 65. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2024) Figure 66. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024) Figure 67. Middle East & Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024) Figure 68. Egypt Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 69. South Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 70. Israel Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 71. Turkey Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 72. GCC Countries Long-acting Injectable Antipsychotics (LAIs) Revenue Growth 2019-2024 ($ millions) Figure 73. Manufacturing Cost Structure Analysis of Long-acting Injectable Antipsychotics (LAIs) in 2023 Figure 74. Manufacturing Process Analysis of Long-acting Injectable Antipsychotics (LAIs) Figure 75. Industry Chain Structure of Long-acting Injectable Antipsychotics (LAIs) Figure 76. Channels of Distribution Figure 77. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Forecast by Region (2025-2030) Figure 78. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Region (2025-2030) Figure 79. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Forecast by Type (2025-2030) Figure 80. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Type (2025-2030) Figure 81. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share Forecast by Application (2025-2030) Figure 82. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Forecast by Application (2025-2030)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Otsuka Pharmaceutical|||CHEPLAPHARM Arzneimittel GmbH|||Alkermes Pharma Ireland Limited|||Essential Pharma|||Janssen Pharmaceuticals|||Indivior UK Limited|||Qilu Pharmaceutical|||Lvye Pharmaceutical